The BIO Investor Forum Links Promising Early-Stage Technologies with an Active Investor Network

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in 2018.  In 2018, venture capital funding of private emerging therapeutic companies also reached a decade high of $12.3 billion, a 56% ($4.4 billion) increase from the prior record set in